Immunological cross-reactivity of anti-drug antibodies to adalimumab and ABP 501

被引：0
|
作者：
Miller, J. [1 ]
Manning, M. Starcevic [1 ]
Wala, I. [1 ]
Wang, H. [1 ]
Krishnan, E. [1 ]
Kaliyaperumal, A. [1 ]
Zhang, N. [1 ]
Mytych, D. [1 ]
机构：
[1] Amgen Inc, Biosimilars, Thousand Oaks, CA 91320 USA
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P055
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [1] Establishing pharmacokinetic equivalence between adalimumab and ABP 501 in the presence of anti-drug antibodies using population PK modelling
    Doshi, S.
    Krishnan, E.
    Wang, H.
    Zhang, N.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S471 - S471
  • [2] Time course of the incidence and magnitude of anti-drug antibodies to adalimumab and ABP 501 among patients on concomitant immunomodulatory therapy
    Mytych, D.
    Miller, J.
    Manning, M. Starcevic
    Wala, I.
    Wang, H.
    Zhang, N.
    Krishnan, E.
    Kaliyaperumal, A.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S490 - S491
  • [3] RELATIONSHIP BETWEEN PHARMACOKINETICS AND ANTI-DRUG ANTIBODY STATUS OF ABP 501, A BIOSIMILAR CANDIDATE TO ADALIMUMAB
    Kaur, P.
    Chow, V.
    Zhang, N.
    Markus, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 714 - 714
  • [4] Development of anti-drug antibodies among those treated with adalimumab and ABP 501 and its impact on serum drug concentration in randomised controlled studies
    Chow, V.
    Kaliyaperumal, A.
    Zhang, N.
    Miller, J.
    Mytych, D.
    Manning, M. Starcevic
    Wala, I.
    Wang, H.
    Krishnan, E.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S309 - S309
  • [5] EVALUATION OF MARKETED KITS FOR MEASUREMENT OF ABP 501, THE FIRST APPROVED ADALIMUMAB BIOSIMILAR, DRUG CONCENTRATION AND ANTI-DRUG ANTIBODY LEVELS IN PATIENT SERUM
    Mytych, Dan
    Manning, Marta Starcevic
    Colbert, Alexander
    Hoofring, Sarah
    Miller, Jill
    Gessner, Melissa
    Chow, Vincent
    Fanjiang, Gary
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1020 - 1020
  • [6] Factors that may influence the development of anti-drug antibodies to adalimumab
    Reinisch, W.
    Rauter, I.
    Chen, L.
    Gessner, M.
    Fanjiang, G.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S429 - S430
  • [7] Adalimumab/infliximabDevelopment of anti-drug antibodies: 7 case reports
    Reactions Weekly, 2018, 1701 (1) : 15 - 15
  • [8] CROSS-REACTIVITY OF ANTI-DNA ANTIBODIES
    NAPARSTEK, Y
    BENYEHUDA, A
    COHEN, IR
    BARTANA, R
    IMMUNOLOGY TODAY, 1990, 11 (11): : 388 - 389
  • [9] CROSS-REACTIVITY OF ANTI-DSDNA ANTIBODIES
    TAYLOR, RP
    EDBERG, JC
    IMMUNOLOGY TODAY, 1987, 8 (03): : 75 - 75
  • [10] Adalimumab/methotrexateLack of efficacy and development of anti-drug antibodies : case report
    Reactions Weekly, 2018, 1724 (1) : 18 - 18
12345